Black Rock Inc. Hepion Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $1.06 $1,613 - $5,518	5,206 Added 0.33%	1,602,772 $1.25 Million
Q4 2022 Feb 13, 2023	BUY	$0.27 - $11.9 $1,291 - $56,941	4,785 Added 0.3%	1,597,566 $479,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $11,186 - $228,124	-21,935 Reduced 1.36%	1,592,781 $805,000
Q2 2022 Aug 12, 2022	BUY	$0.57 - $1.22 $1,190 - $2,548	2,089 Added 0.13%	1,614,716 $924,000
Q1 2022 May 12, 2022	SELL	$0.93 - $1.29 $10,488 - $14,548	-11,278 Reduced 0.69%	1,612,627 $2.08 Million
Q4 2021 Feb 10, 2022	SELL	$1.14 - $1.58 $11,521 - $15,969	-10,107 Reduced 0.62%	1,623,905 $1.85 Million
Q3 2021 Nov 09, 2021	SELL	$1.39 - $2.1 $22,124 - $33,425	-15,917 Reduced 0.96%	1,634,012 $2.5 Million
Q2 2021 Aug 11, 2021	BUY	$1.56 - $2.26 $2.57 Million - $3.73 Million	1,649,929 New	1,649,929 $3.27 Million

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $45.7M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.